

## BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>Angel Augusto Rodriguez</b>	POSITION TITLE  Assistant Professor of Medicine		
eRA COMMONS USER NAME (credential, e.g., agency login)			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)</i>			
INSTITUTION AND LOCATION  Georgia Institute of Technology, Atlanta, GA Universidad Central del Caribe Sch of Medicine Bayamon, PR	DEGREE <i>(if applicable)</i>  B.S.  M.D.	MM/YY  1997  2002	FIELD OF STUDY  Chemistry  Medicine

### A. Personal Statement

Over the last several years, I have benefitted from the guiding hands of several exceptional academicians who invested personal and professional time into my training. It is largely because of the mentoring of these scholars combined with the institutional support that I am inspired to make a difference and strive for excellence in the area of breast cancer research. As Director of the Triple Negative Breast Cancer Clinic at Houston Methodist Cancer Center I have been able to set up a program where patients with high risk and advanced metastatic breast cancer can have access to clinical trials. Our most recent investigator initiated trial was completed and presented in ASCO 2014, preoperative ixabepilone with or without cetuximab for triple negative breast cancer. Another study is a phase 2 single arm study of chloroquine plus a taxane for the treatment of metastatic breast cancer. Five years ago, with the support of Houston Methodist Hospital we set up a breast cancer clinic for underinsured and uninsured patients at Vecino Health Centers. I have been able to create a program where patients coming from a wide range of socioeconomic background can have access to the latest clinical trials. Thanks to Susan G. Komen Breast Health Initiative Grant we are able to see newly diagnosed breast cancer patients without insurance and provide them with the latest treatments through Houston Methodist Foundation Charity Care.

### B. Positions and Honors

#### Employment

2005 – 2008	Hospitalist, St. Luke's Episcopal Hospital, Houston, TX
2008 – 2010	Attending, Ben Taub General Hospital, Houston, TX
2008 – 2011	Attending Physician, Breast Oncology Clinic, Ben Taub General Hospital, Houston, TX
2008 – 2011	Attending Physician, Breast Oncology, Baylor College of Medicine, Houston, TX
2008 – 2011	Clinical Instructor, Baylor College of Medicine, Houston, TX
2011 – present	Breast Oncology, Denver Harbor Clinic, Houston, TX
2011 – present	Breast Oncology, Houston Methodist Cancer Center
2012 – present	Director, Triple Negative Breast Cancer Clinic, Houston Methodist Cancer Ctr, Houston, TX

#### Positions/Honors

2005 – 2008	Hospitalist, St. Luke's Episcopal Hospital
2008 – 2010	Attending, Ben Taub General Hospital
2008 – 2011	Attending Physician, Breast Oncology, Baylor College of Medicine
2008 – 2011	Clinical Instructor, Baylor College of Medicine
2008 – 2011	Breast Oncology Clinic, Ben Taub General Hospital
2011 – present	Houston Methodist Cancer Center
2011 – present	Breast Oncology, Denver Harbor Clinic
2012 - present	Director, Triple Negative Breast Cancer Clinic

#### National Scientific Participation

N/A

## Peer Review Boards (Selected)

### **C. Selected Peer-reviewed Publications** (Selected from more than 100 peer-reviewed publications) **Most relevant publications**

1. Inhibition of INOS as a novel effective targeted therapy against triple negative breast cancer, Stem cells.
2. Tanei T, Choi DS, **Rodriguez AA**, Dobrolecki L, Ghosh M, Landis M, and Chang JC. Antitumor activity of cetuximab in cChoio combination with Ixabepilone of Triple Negative Breast Cancer Stem Cells. Breast Cancer Research, Submitted.
3. Patel TA, Dave B, **Rodriguez AA**, Chang JC, Perez EA, and Colon-Otero G. Dual HER2 blockade: Preclinical and clinical data. Breast Cancer Research, Accepted.
4. Choi DS, Blanco E, Kim YS, **Rodriguez AA**, Zhao H, Huang TH, Chen CL, Jin G, Landis MD, Burey LA, Qian W, Granados SM, Dave B, Wong HH, Ferrari M, Wong ST, Chang JC. Chloroquine eliminates cancer stem cell through deregulation of Jak2 and DNMT1. Stems Cells. 2014 Sept 2(9):2309-23.
5. Chen AC, Paulino AC, Schwartz MR, **Rodriguez AA**, Bass BL, Chang JC, The BS. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer. 2014 Jul 29;111(3):619-22. Doi: 10.1038/bjc.2014.301. Epub 2014 Jun 2012.
6. Chen, AC, Paulina AC, Schwartz MR, **Rodriguez AA**, Bass BL, Chang JC, Teh BS. Progressive markers for invasive micropapillary carcinoma of the breast: a population-based analysis. (CBC MS# CBC-D-12-00103RI)
7. Zhao H, Jin G, Cui K, Ren D, Liu T, Chen P, Wong S, Li F, Fan Y, **Rodriguez AA**, Chang J, Wong ST. Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distric breast cancer metastases. Cancer Res 2013 Oct 15;73(20):6149-63.
8. Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, **Rodriguez AA**, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne Ck, Chang JC. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013 May 10;31(14):1726-31.
9. Yu KD, Zhu R, Zhan M, **Rodriguez AA**, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res 2013 May 15;19(10):2723-33.
10. Chen AC, Paulino AC, Schwartz MR, **Rodriguez AA**, Bass AL, Chang JC, Teh BS. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis. Clin Breast Cancer 2013 Apr 13(2):133-9.
11. Creighton CJ, Sada YH, Zhang Y, Tsimelzon A, Wong H, Dave B, Landis MD, Bear HD, **Rodriguez A**, Chang JC. A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat 2012 Apr 132(3):993-1000.
12. Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, **Rodriguez A**, Chang J, Wong ST. The effect of mTOR inhibition alone or combines with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Res Treat 2011, March 2011.
13. **Rodriguez AA**, Makris A, Wu WF, Froehlich A, Dave B, Hilsenbeck SG, Lewis MT, Rimawi M, Osborne CK, Chang JC. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010 Aug 23(1):189-96.
14. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, **Rodriguez AA**, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Bhuchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA. Characterizing cancer ce3lls with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer 2010 Jul 8;9:180.
15. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, **Rodriguez A**, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D,

Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009 Aug 18;106(33):3820-5.

## **D. Research Support**

### **Ongoing Research Support**

3/2011-12/2013

Title: A screening Study of Patients with Breast Cancer to Evaluate Urine PGE-M levels and Cyclooxygenase 2 Expression in Tumor Samples.

Role: Principal Investigator

9/2011-10/2013

Title: Choosing Neoadjuvant Chemotherapy versus Hormonal Therapy for Breast Cancer Based on Gene Expression Profile.

Role: Principal Investigator

9/2011 – present

Title: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less.

Role: Principal Investigator

9/2011 – present

Title: A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer.

Role: Sub-Investigator

### **Completed Research Support**

N/A